Nyxoah: CEO to Address Investors at Key Conference in March 2026
Nyxoah SA announces its participation in the 36th Annual Oppenheimer Healthcare MedTech & Services Conference, to be held from March 16 to March 19, 2026. The CEO of the medical technology company will present the company to investors.
Olivier Taelman, Chief Executive Officer of Nyxoah, will deliver a presentation about the company on Monday, March 16, 2026, at 8:40 AM Eastern Time. The live webcast of the event will be available on Nyxoah's Investor Relations website and can be viewed on replay after the conference. Nyxoah's investor presentation will be available in the 'Shareholder Information' section of the 'Investor Relations' page on the company's website.
Individual Meetings with Institutional Investors
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Nyxoah will also be available for individual meetings with institutional investors attending the event.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 14 millions d'euros
Quarterly revenue: 14 millions d'euros
Revenue growth: 484,4 %
Net income: -48,9 millions d'euros
Guidance from the release
nous sommes confiants dans le fait que l'environnement de remboursement actuel soutient l'accélération de notre croissance du chiffre d'affaires aux États-Unis
Risks mentioned
Baisse de la marge brute à 59 % au S1 2026 due à des problèmes de rendement de production au T1 et à un mix de revenus américain plus important
Augmentation des charges de vente, générales et administratives liée au déploiement commercial aux États-Unis
Perte opérationnelle en hausse à 41,1 M€ au S1 2026 contre 40,5 M€ au S1 2025
Opportunities identified
Financement de 110 millions de dollars sécurisé au T2 2026 pour financer la croissance commerciale
Taux d'approbation de 100 % sur les demandes d'autorisation préalable pour les patients commerciaux et WISeR
Code Medicare C-code 8011 dédié à Genio, clarifiant le paysage de remboursement
Outlook / guidance
Expected revenue: 38 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
